ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
NexGel Equity Warrant Exp 17th Dec 2026 Warrant
0.0589
-0.0001
-0.17%
成交量：
9,614.00
成交額：
467.70
市值：
47.52萬
市盈率：
-0.16
高：
0.0589
開：
0.0436
低：
0.0400
收：
0.0590
52周最高：
0.4952
52周最低：
0.0377
股本：
806.76萬
流通股本：
806.76萬
量比：
4.51
換手率：
0.12%
股息：
- -
股息率：
- -
每股收益(TTM):
-0.3796
淨資產收益率：
-60.47%
總資產收益率：
-19.51%
市淨率：
0.10
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
Nexgel披露授權與收購商業化階段再生生物材料產品組合協議的具體條款
美股速递
·
03/12
Nexgel達成協議 預計年收入將翻三倍至3500萬美元並實現盈利
美股速递
·
03/12
Nexgel簽署最終協議 獲授權並收購商業化階段再生生物材料產品組合
美股速递
·
03/10
NEXGEL, INC.潛在收購案須待雙方盡職調查完成
美股速递
·
02/10
Nexgel公布179.7萬美元融資計劃 關聯收購交易擬於2026年第一季度完成 盡職調查成關鍵前提
美股速递
·
02/10
NEXGEL, INC.獲得Diesis Holdings, LLC的Eric Gruntfest追加投資，並任命其為董事會觀察員和戰略顧問
美股速递
·
2025/12/16
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NXGLW/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NXGLW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NXGLW\",,,,,undefined,":{"symbol":"NXGLW","market":"US","secType":"STK","nameCN":"NexGel Equity Warrant Exp 17th Dec 2026 Warrant","latestPrice":0.0589,"timestamp":1774035308141,"preClose":0.059,"halted":0,"volume":9614,"delay":0,"changeRate":-0.0016949152542372191,"floatShares":8067580,"shares":8067580,"eps":-0.3796,"marketStatus":"交易中","change":-0.0001,"latestTime":"03-20 15:54:59 EDT","open":0.0436,"high":0.0589,"low":0.04,"amount":467.70446778,"amplitude":0.320339,"askPrice":0.0858,"askSize":5000,"bidPrice":0.0403,"bidSize":300,"shortable":0,"etf":0,"ttmEps":-0.3796,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"listingDate":1640149200000,"exchange":"NASDAQ","adjPreClose":0.059,"volumeRatio":4.507478},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NXGLW\",,,,,undefined,":{"symbol":"NXGLW","floatShares":8067580,"roa":"-19.51%","roe":"-60.47%","lyrEps":0,"volumeRatio":4.507478,"shares":8067580,"dividePrice":0,"high":0.0589,"amplitude":0.320339,"preClose":0.059,"low":0.04,"week52Low":0.0377,"pbRate":"0.10","psRate":"0.04","week52High":0.4952,"institutionHeld":0,"latestPrice":0.0589,"committee":-0.886792,"eps":-0.3796,"divideRate":0,"volume":9614,"delay":0,"ttmEps":-0.3796,"open":0.0436,"prevYearClose":0.2351,"prevWeekClose":0.05,"prevMonthClose":0.1485,"prevQuarterClose":0.2351,"fiveDayClose":0.05,"twentyDayClose":0.1669,"sixtyDayClose":0.197},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NXGLW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NXGLW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NXGLW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NXGLW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1106679764","title":"Nexgel披露授權與收購商業化階段再生生物材料產品組合協議的具體條款","url":"https://stock-news.laohu8.com/highlight/detail?id=1106679764","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106679764?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 21:06","pubTimestamp":1773320791,"startTime":"0","endTime":"0","summary":"Nexgel公司已公布其授权并收购一系列商业化阶段再生生物材料产品组合的协议考量条款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXGL","BK4139","NXGLW","CELU","BK4198"],"gpt_icon":0},{"id":"1134454050","title":"Nexgel達成協議 預計年收入將翻三倍至3500萬美元並實現盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=1134454050","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134454050?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 21:06","pubTimestamp":1773320783,"startTime":"0","endTime":"0","summary":"Nexgel公司近日宣布达成一项具有里程碑意义的合作协议。该交易预计将使公司年收入实现三倍增长，达到3500万美元规模，并在交易完成后立即推动公司实现盈利目标。\n这项战略性合作将显著提升Nexgel在凝胶材料领域的市场地位。收入的大幅增长将为企业带来充足的现金流，为后续的研发投入和市场扩张提供有力支撑。分析指出，此次合作不仅能够快速改善公司的财务状况，还将为长期可持续发展奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXGLW","BK4139","BK4198","CELU","NXGL"],"gpt_icon":0},{"id":"1111760684","title":"Nexgel簽署最終協議 獲授權並收購商業化階段再生生物材料產品組合","url":"https://stock-news.laohu8.com/highlight/detail?id=1111760684","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111760684?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 20:45","pubTimestamp":1773146715,"startTime":"0","endTime":"0","summary":"Nexgel公司已正式签署具有约束力的最终协议，将授权并收购一系列处于商业化阶段的革命性再生生物材料产品组合。该交易标志着公司正式进军高增长潜力的再生医学领域，通过整合成熟技术平台与现有产品线形成协同效应。此次收购的产品组合包含多款经临床验证的生物材料，可广泛应用于创伤修复、组织工程等医疗场景。协议执行后，Nexgel将获得相关产品的全球商业化权利及生产技术，预计将显著增强其在高端医疗器械市场的竞争力。此次战略布局有望为公司开辟新的收入来源，并推动其向综合性生物医学解决方案提供商转型。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELU","BK4198","NXGL","NXGLW","BK4139"],"gpt_icon":0},{"id":"1157188735","title":"NEXGEL, INC.潛在收購案須待雙方盡職調查完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1157188735","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157188735?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 22:07","pubTimestamp":1770732448,"startTime":"0","endTime":"0","summary":"NEXGEL, INC.近期披露的潜在收购交易仍存在不确定性，最终能否达成将取决于收购方与NEXGEL自身尽职调查程序的完整执行。根据公开信息，该交易尚处于初步评估阶段，双方需对财务、法律及运营状况进行全面核查后方可推进。此次潜在收购的推进节奏呈现出明显的阶段性特征：一方面，NEXGEL需要审慎评估收购方案对公司长期战略的契合度；另一方面，投资方也需通过尽职调查验证标的资产的真实价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXGL","BK4198","NXGLW"],"gpt_icon":0},{"id":"1173301360","title":"Nexgel公布179.7萬美元融資計劃 關聯收購交易擬於2026年第一季度完成 盡職調查成關鍵前提","url":"https://stock-news.laohu8.com/highlight/detail?id=1173301360","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173301360?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 22:01","pubTimestamp":1770732075,"startTime":"0","endTime":"0","summary":"生物材料公司Nexgel近日披露一项总额达179.7万美元的融资安排，该资金将专项用于支持一项战略性收购项目。根据最新规划，此次收购交易预计将于2026年第一季度完成最终交割，但最终时间表将取决于尽职调查程序的顺利完成。此次融资方案与收购计划形成紧密联动，体现出公司通过外部扩张实现业务增长的明确战略意图。作为一家专注于先进水凝胶技术研发的企业，Nexgel此次资本运作彰显了其通过并购加速技术商业化进程的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","NXGLW","NXGL"],"gpt_icon":0},{"id":"1164023238","title":"NEXGEL, INC.獲得Diesis Holdings, LLC的Eric Gruntfest追加投資，並任命其為董事會觀察員和戰略顧問","url":"https://stock-news.laohu8.com/highlight/detail?id=1164023238","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164023238?lang=zh_tw&edition=fundamental","pubTime":"2025-12-16 21:02","pubTimestamp":1765890147,"startTime":"0","endTime":"0","summary":"NEXGEL, INC.获得Diesis Holdings, LLC的Eric Gruntfest追加投资，并任命其为董事会观察员和战略顾问","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","NXGL","NXGLW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}